CA2016504A1 - Methode et produits intermediaires pour la preparation d'acides oxophtalazinylacetiques et de leurs analogues - Google Patents

Methode et produits intermediaires pour la preparation d'acides oxophtalazinylacetiques et de leurs analogues

Info

Publication number
CA2016504A1
CA2016504A1 CA2016504A CA2016504A CA2016504A1 CA 2016504 A1 CA2016504 A1 CA 2016504A1 CA 2016504 A CA2016504 A CA 2016504A CA 2016504 A CA2016504 A CA 2016504A CA 2016504 A1 CA2016504 A1 CA 2016504A1
Authority
CA
Canada
Prior art keywords
oxophthalazinyl
acetic acids
thioacetamide
analogs
intermediates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2016504A
Other languages
English (en)
Other versions
CA2016504C (fr
Inventor
William J. Zembrowski
Banavara L. Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of CA2016504A1 publication Critical patent/CA2016504A1/fr
Application granted granted Critical
Publication of CA2016504C publication Critical patent/CA2016504C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA002016504A 1989-05-11 1990-05-10 Methode et produits intermediaires pour la preparation d'acides oxophtalazinylacetiques et de leurs analogues Expired - Fee Related CA2016504C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/350,997 US4954629A (en) 1989-05-11 1989-05-11 Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US350,997 1989-05-11

Publications (2)

Publication Number Publication Date
CA2016504A1 true CA2016504A1 (fr) 1990-11-11
CA2016504C CA2016504C (fr) 1999-07-27

Family

ID=23379152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002016504A Expired - Fee Related CA2016504C (fr) 1989-05-11 1990-05-10 Methode et produits intermediaires pour la preparation d'acides oxophtalazinylacetiques et de leurs analogues

Country Status (30)

Country Link
US (1) US4954629A (fr)
EP (1) EP0397350B1 (fr)
JP (1) JPH035479A (fr)
KR (1) KR920006419B1 (fr)
CN (1) CN1025855C (fr)
AR (1) AR246968A1 (fr)
AT (1) ATE103913T1 (fr)
AU (2) AU618898B2 (fr)
BG (1) BG50609A3 (fr)
CA (1) CA2016504C (fr)
CZ (1) CZ281213B6 (fr)
DD (1) DD294257A5 (fr)
DE (1) DE69007846T2 (fr)
DK (1) DK0397350T3 (fr)
EG (1) EG19082A (fr)
ES (1) ES2063265T3 (fr)
FI (1) FI93959C (fr)
HU (1) HU212304B (fr)
IE (1) IE62591B1 (fr)
IL (3) IL94301A (fr)
MX (2) MX167455B (fr)
NO (1) NO177708C (fr)
NZ (1) NZ233597A (fr)
PH (1) PH26567A (fr)
PL (1) PL164427B1 (fr)
PT (1) PT93985B (fr)
RO (1) RO107256B1 (fr)
RU (1) RU2014333C1 (fr)
YU (1) YU91290A (fr)
ZA (1) ZA903565B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
EP0982306A3 (fr) * 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorphe du monohydrate de zopolrestat
HRP20221430T1 (hr) * 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN102558184B (zh) * 2011-12-30 2014-07-16 西南大学 酞嗪类衍生物的合成方法
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
RS61239B1 (sr) 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (fr) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibiteurs de l'aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DE3337859A1 (de) * 1983-01-21 1984-07-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von benzthiazolen
CA1299178C (fr) * 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Acides oxophtalazinylacetiques heterocycliques
DE3684410D1 (de) * 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0322153A3 (fr) * 1987-12-21 1990-08-16 Pfizer Inc. Acides hétérocyclyl oxophtalazinyl acétiques
WO1989006651A1 (fr) * 1988-01-19 1989-07-27 Pfizer Inc. Acides 1h-indazole-3-acetiques servant d'inhibiteurs d'aldose reductase
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors

Also Published As

Publication number Publication date
HU902995D0 (en) 1990-09-28
IL114271A0 (en) 1995-10-31
BG50609A3 (en) 1992-09-15
KR920006419B1 (ko) 1992-08-06
DE69007846D1 (de) 1994-05-11
NO902071L (no) 1990-11-12
AU626225B2 (en) 1992-07-23
US4954629A (en) 1990-09-04
IL114271A (en) 1998-04-05
YU91290A (sh) 1992-09-07
PL164427B1 (pl) 1994-07-29
FI902333A0 (fi) 1990-05-10
HUT54690A (en) 1991-03-28
DK0397350T3 (da) 1994-05-09
IL94301A (en) 1996-01-19
AU618898B2 (en) 1992-01-09
ATE103913T1 (de) 1994-04-15
MX167455B (es) 1993-03-23
IE62591B1 (en) 1995-02-08
AR246968A1 (es) 1994-10-31
RO107256B1 (ro) 1993-10-30
FI93959B (fi) 1995-03-15
ES2063265T3 (es) 1995-01-01
DD294257A5 (de) 1991-09-26
CN1025855C (zh) 1994-09-07
IL94301A0 (en) 1991-03-10
CZ227890A3 (en) 1996-04-17
CZ281213B6 (cs) 1996-07-17
NO902071D0 (no) 1990-05-10
IE901626L (en) 1990-11-11
AU8680691A (en) 1992-01-02
JPH0573753B2 (fr) 1993-10-15
RU2014333C1 (ru) 1994-06-15
ZA903565B (en) 1991-12-24
HU212304B (en) 1996-05-28
NO177708C (no) 1995-11-08
EP0397350A1 (fr) 1990-11-14
NZ233597A (en) 1992-02-25
KR900018114A (ko) 1990-12-20
EP0397350B1 (fr) 1994-04-06
PT93985A (pt) 1991-01-08
AU5490690A (en) 1990-11-15
NO177708B (no) 1995-07-31
CN1047499A (zh) 1990-12-05
PL285113A1 (en) 1991-07-15
JPH035479A (ja) 1991-01-11
DE69007846T2 (de) 1994-07-28
CA2016504C (fr) 1999-07-27
PT93985B (pt) 1996-11-29
PH26567A (en) 1992-08-19
MX9207687A (es) 1994-06-30
FI93959C (fi) 1995-06-26
EG19082A (en) 1994-07-30

Similar Documents

Publication Publication Date Title
CA2016504A1 (fr) Methode et produits intermediaires pour la preparation d'acides oxophtalazinylacetiques et de leurs analogues
AU5215990A (en) Zipper closure with internal peel seal
ES8103048A1 (es) Un procedimiento para preparar derivados del acido 4-amino-3-quimoleincarboxilico.
EP0557996A3 (en) Process for the production of amino acids by fermentation
DE69308709D1 (de) Verfahren zur Herstellung eines direktwirkender Ventilstössels
AU6755081A (en) Pipe coupling with improved sealing ring
DE3889398D1 (de) Verfahren zur Herstellung eines Supraleiters.
DE69104921D1 (de) Verfahren zur Herstellung eines Bismut-Supraleiters.
ATE3145T1 (de) Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung.
GB2025408B (en) Process for the production of tertiary amine having long chain alkyl group
CA2226407A1 (fr) Element de serrage
MY104941A (en) Process for the preparation of 4-demethox- ydaunomycinone, the aglycone of 4-demethoxy -daunorubicin.
GR3020486T3 (en) Process for the enzymatic preparation of beta-lactams
FI954786A0 (fi) Menetelmä aminometaanifosfonihapon valmistamiseksi
HK21689A (en) Process for improving the fastness properties of dyestuffs or optical brightners on substrates
DE69417805D1 (de) Verfahren zur Herstellung eines Halbleitermaterials
AU3084989A (en) Precipitation-hardenable nickel-base superalloy with improved mechanical properties in the temperature range from 600 to 750 degrees c.
AU552716B2 (en) N-(p-sulfophenyl)-cinnamamide
AU537839B2 (en) A process for the preparation of (2-aminothiazol-4-yl)-acetic acid hydrochloride
GB1514670A (en) Removing 4-coupled products from azo dyestuffs derived from 1-naphthol series coupling components
JPS56169695A (en) Novel organic compound, its manufacture and its use as coupling component for azo dye production
AU8402982A (en) Inoculation procedure for xanthan gum production
AU5371490A (en) A process for the preparation of glucosaminyl-epi- podophyllotoxin derivatives DO NOT SEAL CASE TO LAPSE
DE69421007D1 (de) Verfahren zur Herstellung eines Halbleitermaterials
DE3682379D1 (fr)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed